arrow
B

Bram De Laere

karolinska institutet
H指数:20
被引数:1,712

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical Trial Protocol for ProBio-mHSPC: A ctDNA-driven De-escalation and Intensification Platform Trial for Metastatic Hormone-sensitive Prostate Cancer

ProBio-mHSPC临床试验方案:一项针对转移性激素敏感前列腺癌的ctDNA驱动的降级与强化平台试验

2026-05-120
PRE
Genomic Predictors of Response to Metastasis-directed Therapy With or Without Androgen Deprivation Therapy

转移灶定向治疗的基因组预测因子:含或不含雄激素剥夺治疗

2025-09-200
PREAI
Prognostic Value of the Circulating Tumor DNA Fraction in Metastatic Castration-resistant Prostate Cancer: Results from the ProBio Platform Trial

Crippa, A.; De Laere, B.; Discacciati, A.; Larsson, B.; Persson, M.; Johansson, S.; D’hondt, S.; Hjälm-Eriksson, M.; Pettersson, L.; Enblad, G.; 等. 循环肿瘤DNA分数在转移性去势抵抗性前列腺癌中的预后价值:ProBio平台试验结果. Eur. Urol. Oncol. 2025. [Google Scholar] [CrossRef]

2025-04-210
OAAI
Efficacy of carboplatin in patients with metastatic castration-resistant prostate cancer: Results from the biomarker-driven, randomised, outcome-adaptive ProBio trial

卡铂在转移性去势抵抗性前列腺癌患者中的疗效:来自生物标志物驱动的、随机、结果适应性ProBio试验的结果

2024-09-011
PRE
Prognostic value of circulating tumour DNA fraction in metastatic castration-resistant prostate cancer: Insights from the ProBio trial

循环肿瘤DNA比例在转移性去势抵抗性前列腺癌中的预后价值:ProBio试验的见解

2024-09-010
PRE
PSA trajectories and prediction of time to no-longer clinically benefitting in metastatic castration-resistant prostate cancer: Insights from the ProBio trial

PSA轨迹及预测转移性去势抵抗性前列腺癌中临床获益终止时间的分析:ProBio试验的见解

2024-09-010
PRE
Health-related quality of life outcomes of androgen receptor pathway inhibitors versus taxanes versus standard of care in metastatic castration-resistant prostate cancer: Results from the ProBio trial

雄激素受体通路抑制剂与紫杉烷类药与标准治疗在转移性去势抵抗性前列腺癌中的健康相关生活质量结局:ProBio试验结果

2024-09-010
PRE
Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial (Aug, 10.1038/s41591-024-03204-2, 2024)
2024-08-280
OAAI
Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial

雄激素受体途径抑制剂和紫杉烷类药物在转移性前列腺癌中的应用: 一项结果适应性随机平台试验

2024-08-201
OAAI
Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer
2024-02-2813
OAAI
Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping
2024-01-0411
PRE
Androgen receptor pathway inhibitors or taxanes for patients with metastatic castration-resistant prostate cancer: A direct comparison in ProBio, a randomized, outcome-adaptive, biomarker-driven platform trial
2023-10-011
PRE
Overcoming complex polyclonality for accurate clinical genotyping in metastatic prostate cancer
2023-06-020
PRE
WNT Pathway Mutations in Metachronous Oligometastatic Castration-Sensitive Prostate Cancer
2023-04-019
OAAI